Setmelanotide (Imcivree): Evidence, Mechanism & Legal Status

Setmelanotide (Imcivree, formerly RM-493) is a synthetic disulfide-cyclized octapeptide that agonizes the melanocortin-4 receptor (MC4R), re-activating the hypothalamic leptin-melanocortin satiety pathway when it is broken by upstream genetic defects.13 It is the first precision therapy to target the root cause of specific rare genetic obesities rather than treating obesity generically. This monograph separates what is proven from what is hyped.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Setmelanotide is an FDA-approved prescription drug used under specialist supervision after genetic or diagnostic confirmation. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is setmelanotide and how does it work?

Setmelanotide is a synthetic disulfide-cyclized octapeptide (8 amino acids) that retains the specificity of alpha-melanocyte-stimulating hormone (alpha-MSH), the endogenous POMC-derived MC4R ligand, while being more potent and longer-lived than native alpha-MSH.13 It binds human MC4R with high affinity (Ki approximately 2.1 nM) and activates it potently (EC50 approximately 0.27 nM), with roughly 20-fold lower activity at MC3R and MC1R, and it can cross into the hypothalamus to act on central MC4R.13

The pathway is the heart of the mechanism. Leptin signals via the leptin receptor (LEPR) on hypothalamic POMC neurons, driving POMC processing by the protease PCSK1 into alpha-MSH, which activates MC4R to increase satiety and energy expenditure.14 Loss-of-function variants in POMC, PCSK1 or LEPR — or ciliopathy-driven pathway impairment in Bardet-Biedl syndrome, or hypothalamic injury in acquired hypothalamic obesity — reduce alpha-MSH signaling at MC4R, producing insatiable hunger (hyperphagia) and early-onset severe obesity.1 Setmelanotide restores the impaired MC4R-pathway activity downstream of these defects.14 Administered subcutaneously, it has an effective elimination half-life of about 11 hours, supporting once-daily dosing, and roughly 39 percent of a dose is excreted unchanged in urine over 24 hours.10

What is the evidence by indication?

Unlike many marketed peptides, setmelanotide carries completed phase 3 human trials. Every indication below is human evidence, graded A — but the grade applies only to these specific, confirmed diagnoses.

In the pivotal phase 3 POMC-deficiency trial (NCT02896192), patients aged 6 and older received open-label setmelanotide for 12 weeks, and responders entered an 8-week double-blind placebo-controlled withdrawal phase; 8 of 10 (80 percent) achieved at least 10 percent weight loss at about one year, with a mean change in the worst-hunger score of negative 27.1 percent (p=0.0005).28 In the parallel LEPR trial, 5 of 11 (45 percent) achieved at least 10 percent weight loss, with hunger scores falling 43.7 percent (p<0.0001), and no serious treatment-related adverse events occurred in either trial.29

The Bardet-Biedl syndrome trial (NCT03746522) randomized patients 1:1 to up to 3.0 mg/day setmelanotide or placebo for a 14-week double-blind period, then open-label; it met its primary endpoint, with about 32 percent of BBS patients losing at least 10 percent of body weight at 52 weeks, though results were inconclusive for Alstrom syndrome.34 A 2026 matched-registry comparison found significantly more patients meeting the primary endpoint than controls (58.6 percent vs 6.9 percent; p<0.001).5 Most recently, the pivotal phase 3 TRANSCEND trial in acquired hypothalamic obesity randomized 142 patients 2:1 and produced a negative 15.8 percent BMI change versus positive 2.6 percent on placebo (placebo-adjusted negative 18.4 percent; p<0.0001), supporting the March 2026 FDA approval.716 Expansion to children as young as 2 was supported by the VENTURE trial.6

What doses appear in the literature?

Reported strictly as information, not a protocol. The route is subcutaneous injection once daily into the abdomen, thigh or upper arm, supplied as a multidose vial.10 The reported titration starts at 0.5 mg (0.05 mL) once daily for about two weeks; if tolerated, it increases to 1 mg, then to a maintenance dose of 1.5 mg (0.15 mL) once daily, with the label permitting up to 3.0 mg depending on age, indication and tolerability.10 The label advises evaluating weight or BMI response at about 12 to 16 weeks and discontinuing if reduction is below 5 percent.13 No change is needed for mild or moderate renal impairment, but the drug is not recommended in end-stage renal disease.10 Because this is the approved branded product, the only legitimate supply is a dispensed prescription — not research-grade vials.

How safe is setmelanotide?

The most common adverse reactions (incidence at or above 20 percent) are skin hyperpigmentation, injection-site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression and spontaneous penile erection.1021 Because melanocytes express MC1R, agonism drives melanin accumulation independent of UV, causing generalized skin darkening, darkening of pre-existing moles and new melanocytic nevi — reversible on discontinuation, but the label mandates skin exams before and during treatment, with chronic melanocyte stimulation a theoretical melanoma concern.13 Spontaneous penile erections occurred in 24 percent of males aged 6 and older, attributed to MC4R modulation of central sexual processing, with patients advised to seek emergency care for erections lasting more than four hours.10 Depression, depressed mood and suicidal ideation have occurred and require monitoring; serious hypersensitivity including anaphylaxis has been reported.10 Weight loss is not advised in pregnancy, and the multidose formulation contains benzyl alcohol, so use is generally avoided in pregnancy and breastfeeding absent compelling benefit.13

What is the FDA and WADA status in 2026?

Setmelanotide is a fully FDA-approved prescription drug, not a research chemical. Imcivree (NDA 213793) received initial approval in November 2020 for chronic weight management in patients aged 6 and older with POMC, PCSK1 or LEPR deficiency confirmed by an FDA-approved genetic test.1511 The label then expanded to Bardet-Biedl syndrome (June 2022), to children aged 2 and older for BBS and the genetic deficiencies (December 2024), and to acquired hypothalamic obesity for ages 4 and older on March 19, 2026 after Priority Review.171619 It is also authorized in the EU and the UK for genetically confirmed BBS and POMC/PCSK1/LEPR deficiency.4 Because it is a commercially available branded drug, it is dispensed as the approved product; any non-pharmacy research setmelanotide is unapproved and outside legitimate channels.

For athletes the picture is more nuanced than for a banned research peptide. Setmelanotide is not specifically named on the 2026 WADA Prohibited List, but as a peptide-hormone mimetic acting on the melanocortin system it could plausibly be argued under category S2.2223 There is no legitimate performance indication for it, so its only relevance to athletes is as an anti-doping consideration. Any tested athlete should verify current status via GlobalDRO and seek a Therapeutic Use Exemption where medically indicated.22

Bottom line. Setmelanotide is a genuine precision-medicine success — Grade A human evidence supports clinically meaningful weight loss and large reductions in hyperphagia in a narrowly defined set of patients whose MC4R satiety pathway is broken by upstream genetic defects or hypothalamic injury. What is proven is benefit in these confirmed indications; what is unsupported is any use as a general weight-loss peptide. Key uncertainties include small sample sizes inherent to ultra-rare diseases, the theoretical long-term melanocytic-tumor risk from chronic melanocyte stimulation, and unknowns in elderly, hepatic and pregnant populations. Regulatory facts here are current as of June 2026 and should be re-verified for any later changes.